发明名称 Method for the treatment of Dravet Syndrome
摘要 A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
申请公布号 US9610260(B2) 申请公布日期 2017.04.04
申请号 US201414447253 申请日期 2014.07.30
申请人 The Katholieke Universiteit Leuven;University Hospital Antwerp 发明人 Ceulemens Berten;Lagae Lieven
分类号 A61K31/135;A61K31/137;A61K45/06;A61K31/19;A61K31/36;A61K31/5513 主分类号 A61K31/135
代理机构 Bozicevic, Field & Francis LLP 代理人 Bozicevic Karl;Bozicevic, Field & Francis LLP
主权项 1. A method of treating seizures in a patient diagnosed with Dravet syndrome and exhibiting a mutation in one, some or all of the genes selected from the group consisting of SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD and PCDH19 comprising administering to said patient an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof; administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient; administering an effective dose of a valproate or a pharmaceutically acceptable salt thereof to said patient; and administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient, whereby seizures are ameliorated in the patient exhibiting the mutation.
地址 Leuven BE